Edwards Lifesciences (NYSE:EW) Given New $118.00 Price Target at UBS Group

Edwards Lifesciences (NYSE:EW) had its price target hoisted by analysts at UBS Group from $110.00 to $118.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. UBS Group‘s price target points to a potential upside of 17.18% from the stock’s previous close.

EW has been the topic of a number of other research reports. Citigroup raised their price objective on Edwards Lifesciences from $110.00 to $117.00 and gave the company a “buy” rating in a report on Thursday. BTIG Research upped their target price on shares of Edwards Lifesciences from $110.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday. Piper Sandler reiterated an “overweight” rating and issued a $115.00 target price (up from $101.00) on shares of Edwards Lifesciences in a research report on Thursday. Barclays raised their price target on shares of Edwards Lifesciences from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Leerink Partners boosted their price target on shares of Edwards Lifesciences from $101.00 to $112.00 and gave the stock an “outperform” rating in a research report on Thursday. Twenty-three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $108.88.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded up $1.33 during mid-day trading on Thursday, reaching $100.70. 9,233,527 shares of the stock traded hands, compared to its average volume of 4,532,402. The business has a 50-day moving average of $88.68 and a 200 day moving average of $85.69. Edwards Lifesciences has a fifty-two week low of $74.66 and a fifty-two week high of $104.17. The stock has a market capitalization of $57.99 billion, a PE ratio of 57.88, a PEG ratio of 2.49 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.06. The firm had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The business’s revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 earnings per share. On average, analysts predict that Edwards Lifesciences will post 3.00 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the business’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the transaction, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel Lippis sold 619 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 5,045 shares of company stock worth $451,596. 0.31% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Edwards Lifesciences in the 2nd quarter valued at about $5,318,092,000. Varma Mutual Pension Insurance Co purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $11,168,000. Conway Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $954,000. Commerce Bank acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $3,121,000. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Edwards Lifesciences by 50.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,719,271 shares of the medical research company’s stock worth $234,727,000 after buying an additional 906,345 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

More Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Q3 results and outlook beat expectations. Edwards reported adjusted EPS of $0.80 versus $0.74 expected and revenue of $1.72 billion versus $1.68 billion, with sales up 11.2% year over year. Strength in structural heart therapies supported margin growth, and the company raised its full-year adjusted EPS outlook to $2.97–$3.05. Edwards Q3 earnings and revenue
• Positive Sentiment: Growth across key therapies supports the outlook. TMTT sales surged 45.6% and TAVR sales grew 8.8%. The company also expects procedure volumes to benefit from positive study results and expanded Medicare reimbursement. Q3 earnings call highlights
• Positive Sentiment: Clinical findings may broaden the addressable market. PROGRESS Trial data indicated TAVR reduced combined death or heart-failure outcomes versus active surveillance in at-risk patients with moderate aortic stenosis, with fewer heart-failure hospitalizations and better quality-of-life measures. PROGRESS Trial data
• Positive Sentiment: Analysts raised targets and ratings. Several firms lifted price targets, including Barclays to $120, Citigroup to $117 and JPMorgan to $120. Baird and Truist upgraded the stock, while multiple firms reiterated positive ratings, reflecting increased confidence after the quarterly report.
• Negative Sentiment: Competition remains a risk. Edwards’ CEO cautioned that more competition is coming in the TAVR market, which could pressure future growth or market share. CEO comments on TAVR competition

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.